Amphetamine Stimulant Prodrug denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applied a Quantity Limit

Cigna places quantity limits on amphetamine-class stimulant prodrugs to align dispensing with standard-of-care prescribing patterns and controlled-substance safety guidelines. A quantity-limit denial means the prescription as written — whether in terms of units per fill, days' supply, or total authorized amount — exceeds Cigna's default coverage parameters for this drug class. This is one of the most common denials for stimulant medications and one of the most frequently overturned on appeal when clinical need is clearly documented.

## Your Appeal Rights

Quantity-limit denials are reviewable coverage decisions. ACA §2719 and ERISA §503 guarantee your right to a full internal appeal and, if needed, independent external review. The external-review option is generally available for approximately four months after a final internal denial. Expedited review (72-hour decision) is available when delay would seriously jeopardize your health or ability to function.

## Appeal Process and Timeline

1. Get the denial letter specifying the limit applied and the clinical policy that sets it. 2. Ask your prescriber to initiate or co-sign the appeal — quantity-limit exceptions require clinical justification from the treating provider. 3. Submit the internal appeal within Cigna's deadline (typically 180 days from denial). Cigna must respond within 30 days (pre-service) or 60 days (post-service). 4. If denied internally, request independent external review through Cigna or your state insurance commissioner.

## Documentation to Gather

• Current prescription details: The exact quantity prescribed and the clinical rationale for that quantity (e.g., titration phase, body weight considerations per the prescribing label, documented clinical response).
• FDA prescribing label: Download from DailyMed and note the dosing guidance relevant to your situation. The label, not the insurer's default, defines the medically appropriate dose range.
• Prescriber letter: The prescriber should explain why the prescribed quantity is medically necessary, citing the FDA label and the patient's clinical response to date.
• Treatment history: Prior stimulant trials, dose adjustments, and outcomes — showing that the current prescription reflects a considered clinical judgment rather than a first attempt.
• Cigna's quantity-limit policy: Obtain the current policy and identify what clinical exceptions are recognized.

## Criteria-Mapping Structure

Cigna's quantity-limit exception policy will list conditions under which a higher quantity may be approved. Build a table with each exception criterion in the left column and the chart evidence satisfying it in the right. Attach the FDA label page showing the relevant dosing range as a supporting exhibit. The goal is to demonstrate that the prescribed quantity is within the labeled therapeutic range and is clinically individualized — not an arbitrary excess.